Table 3.
Factors associated with relevant fatigue: univariate analysis
| Characteristic | Relevant fatigue (CFQ ≥ 4) | No fatigue (CFQ < 4) | p‐value |
|---|---|---|---|
| n (%) | 110 (56.1) | 86 (43.9) | |
| Age, year, mean (SD) | 59 (17) | 58 (16) | .951 |
| Age at disease onset, mean (SD) | 48 (20) | 48 (21) | .975 |
| Female sex, n (%) | 68 (66.0) | 35 (34.0) | .003 |
| Disease duration, year, median (IQR) | 7 (3–14) | 5 (2–15) | .881 |
| QMG score, mean (SD) | 9.9 (6.0) | 4.4 (4.0) | <.001 |
| ISI score, mean (SD) | 11.6 (7.2) | 5.5 (5.1) | <.001 |
| ISI ≥ 10 points, n (%) | 63 (79.7) | 16 (20.3) | |
| HADS‐D, mean (SD) | 6.5 (3.6) | 2.2 (2.4) | <.001 |
| HADS‐D ≥ 8 points, n (%) | 34 (89.5) | 4 (10.5) | |
| HADS‐A, mean (SD) | 6.9 (3.8) | 3.8 (3.2) | <.001 |
| HADS‐A ≥ 8 points, n (%) | 42 (77.8) | 12 (22.2) | |
| Antibody status, n (%) | |||
| AchR | 85 (52.5) | 77 (47.5) | .033 |
| MuSK | 6 (100) | 0 (0.0) | .035 |
| Negative | 18 (66.7) | 9 (33.3) | .225 |
| Medication, n (%) | |||
| Cholinesterase inhibitors | 100 (59.2) | 69 (40.8) | .031 |
| Glucocorticoids | 67 (60.4) | 44 (39.6) | .172 |
| Immunosuppressants | 69 (61.1) | 44 (38.9) | .104 |
| None | 1 (25.0) | 3 (75.0) | .321 |
| Thymectomy, n (%) (9 missings) | 60 (63.2) | 35 (36.8) | .050 |
| Thymoma | 11 (47.8) | 12 (52.2) | .080 |
| Thymus hyperplasia | 18 (62.1) | 11 (37.9) | .884 |
| Comorbidities | |||
| Other immunopathies | 34 (68.0) | 16 (32.0) | .050 |
| Malignancies | 3 (42.9) | 4 (57.1) | .701 |
| NYHA | 5 (83.3) | 1 (16.7) | .233 |
| Comedication, n (%) | |||
| Antidepressants | 13 (72.2) | 5 (27.8) | .149 |
| NSAIDs | 9 (75.0) | 3 (25.0) | .174 |
| Opioids | 8 (100.0) | 0 (0.0) | .011 |
QMG, quantitative myasthenia gravis score; ISI, Insomnia Severity Index; HADS, Hospital Anxiety and Depression Scale; HADS‐D, HADS‐Depression; HADS‐A, HADS‐Anxiety; AchR, acetylcholine receptor; MuSK, muscle‐specific tyrosine kinase; CFQ, Chalder Fatigue Scale.